Development and Evaluation of PLGA Nanoparticles Loaded Allicin for Breast Cancer

Abstract

The objective of this work was to design and develop Poly (D, L-Lactide-co-glycolide) (PLGA) Nanoparticles (NPs) of Allicin for treatment of breast cancer by Double Emulsification and Precipitation technique using stabilizer (poly vinyl alcohol). A systemic integration of design of experiment (DoE) based approach to design and to control process parameters yielded optimized final products. Three independent factors such as PLGA 50:50 (A), PVA (B), stirring speed (C) were considered. Three dependent responses were recorded in the experiment; Allicin release in 12^th hour (Response 1), entrapment efficiency (Response 2) & particle size (Response 3). ATR and DSC studies indicated that there was no interaction between the drug and polymer. The morphological studies performed by SEM showed uniform and spherical shaped discrete particles without aggregation and smooth in surface morphology with a nano size range of 198.9 nm. X-ray diffraction was performed to reveal the crystalline nature of the drug after encapsulation. The NPs formed were spherical in shape with zeta potentials (4.4 mV). In vitro release studies were revealed drug release up to 12 hours.  Allicin release kinetics study ascertained by First order kinetic study. Whereas release mechanism observed that, most of the formulations obeyed Higuchi. The cell viability was still more than 80% after incubation with the ALLICIN NP for 24 hours up to a concentration of 80 μg/ml. The Allicin NP carrier -treated MCF-7 display intrinsic cell damage and cell shrinkages compared with the control group. From the present investigation, it was concluded that PLGA NPs of Allicin may effectively deliver the drug and treats breast cancer.